Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Welcomes Mandatory eCTD In Australia, But With Caveats

Executive Summary

The Australian regulator, TGA, is currently assessing responses to last year’s consultation on the mandatory use of the eCTD for prescription drug submissions. Industry is mostly happy with the proposal, but has some concerns over the implementation process and certain technical issues.

You may also be interested in...



Singapore Reveals Phase-In Plans For eCTD

The Health Sciences Authority will seek industry’s feedback on the plans it has for introducing in Singapore the electronic format of the common technical document that drug companies use to make their regulatory submission.

Australia To Make eCTD Mandatory From 2020

The Therapeutic Goods Administration plans to make the electronic CTD format mandatory for all prescription drug submissions from July 2020, saying this will reduce the time and cost involved in making and evaluating regulatory submissions and bring Australia into line with other international regulators.

UK Reveals Plans For ‘Dynamic’ Post-Brexit Regulatory System

At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.

Topics

UsernamePublicRestriction

Register

PS124543

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel